<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01533298</url>
  </required_header>
  <id_info>
    <org_study_id>CW-CFO-301</org_study_id>
    <nct_id>NCT01533298</nct_id>
  </id_info>
  <brief_title>A Safety, Efficacy Study of CombiflexOmega Peri Versus SmofKabiven Peripheral in Patients With Parenteral Nutrition</brief_title>
  <acronym>OMEGA</acronym>
  <official_title>A Randomized, Open, Multicenter, Compared Phase III Trial to Evaluate the Safety, Efficacy of CombiflexOmega Peri and SmofKabiven Peripheral in Postoperative Patients Requiring Parenteral Nutrition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>JW Life Science</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>JW Pharmaceutical</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the safety and efficacy of CombiflexOmega peri in
      comparison to SmofKabiven peripheral in postoperative patients requiring parenteral
      nutrition.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of adverse drug reaction</measure>
    <time_frame>4days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes of laboratory parameters (biochemistry, hematology, coagulation)</measure>
    <time_frame>5days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of vital signs</measure>
    <time_frame>5days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Parent</condition>
  <arm_group>
    <arm_group_label>CombiflexOmega peri</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SmofKabiven peripheral</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CombiflexOmega peri</intervention_name>
    <description>intravenously over 3 days infusion</description>
    <arm_group_label>CombiflexOmega peri</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SmofKabiven peripheral</intervention_name>
    <description>intravenously over 3 days infusion</description>
    <arm_group_label>SmofKabiven peripheral</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 20 and older

          -  Patients are expected to require PN for more than 3 days

          -  Patients who voluntarily signed the consent form

        Exclusion Criteria:

          -  Patients are expected difficult to survive more than 3 days

          -  Pregnant or breast-feeding women

          -  BMI &gt; 30 kg/m2

          -  Patients with severe blood coagulation disorders

          -  Patients with congenital amino acid metabolism disorders

          -  Patients with acute shock

          -  Patients with uncontrollable diabetes mellitus

          -  Patients with hemophage syndrome

          -  Patients with hypopotassemia (K &lt; 3.0mEq/L)

          -  Patients having the history of myocardial infarction

          -  Patients reported the following laboratory value

               -  fasting TG &gt; 250mg/dl, TC &gt; 300mg/dl

               -  ALT/AST ≥ 2×ULN, Bilirubin ≥ 3mg/dl (Exception : patients with periampullary
                  carcinoma including biliary tract or pancreas)

               -  Creatinine ≥1.5mg/dl

               -  Ca &gt; 11.2mg/dl, Na ≥ 145mEq/L, Mg ≥ 2.1mEq/L, K ≥ 5.5mEq/L

          -  Patients having hypersensitivity to any peanut-, fish-, soy-, egg protein, or
             investigational drug

          -  Patients having the history of drug or alcohol abuse

          -  General contraindications to infusion therapy: acute pulmonary oedema, hyperhydration,
             cardiac decompensation

          -  Patients are in unstable conditions

          -  Patients with difficult peripheral intravenous

          -  Patients with parenteral nutrition within 7 days prior to start of the trial

          -  Participation in another clinical study with an investigational drug or an
             investigational medical device within 28 days prior to start of study

          -  Patients judged to be unsuitable for this trial by investigators
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 18, 2012</study_first_submitted>
  <study_first_submitted_qc>February 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2012</study_first_posted>
  <last_update_submitted>February 15, 2013</last_update_submitted>
  <last_update_submitted_qc>February 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

